People living with HIV (PLWH) have persistently elevated levels of inflammation and immune activation despite suppressive antiretroviral therapy (ART). Because adaptive immune responses against HIV persist in PLWH on ART, and show evidence of ongoing antigenic stimulation, we hypothesized that they contribute to this phenomenon. We therefore investigated potential associations between HIV-specific T-cell and antibody responses with on-ART inflammation and immune activation.
T-cell responses (IFN-? ELISPOT) to each HIV gene product as well as to CMV-pp65, and HIV-specific antibody concentrations, were measured in n=101 virally suppressed participants from the AIDS Clinical Trials Group A5321 cohort at study entry (median 7 years on ART). HIV persistence measures including cell-associated (CA)-DNA, CA-RNA, and plasma HIV RNA by integrase single-copy assay (iSCA) were also assessed. Plasma inflammatory biomarkers and T-cell activation and cycling biomarkers were measured at a pre-ART time point and at study entry.
Magnitudes of HIV-specific T-cell responses, CMV-pp65-specific responses, and HIV antibody levels were not correlated with levels of inflammatory or immune activation biomarkers, including hs-CRP, IL-6, neopterin, sCD14, sCD163, %CD38+HLA-DR+ CD8+ and CD4+ cells, and %Ki67+ CD8+ and CD4+ cells – including after adjustment for pre-ART biomarker level. Magnitudes of T-cell responses to HIV-Pol were correlated with TNF-? levels, but this was confounded by several factors jointly including pre-ART plasma viral load, CD4+ T-cell count, and CD4+/CD8+ T-cell ratio, years on ART at A5321 entry, and age at A5321 entry. iSCA levels were correlated with CD8+ T-cell activation (r = 0.25, p = 0.027), but other HIV persistence parameters were not associated with these biomarkers. In statistical mediation analysis, relationships between HIV persistence parameters and inflammatory biomarkers were not mediated or influenced by either HIV-specific T-cell responses or antibody levels.
HIV-specific immune responses do not appear to contribute to inflammation and immune activation under long-term ART. These results add to evidence that pre-therapy pathogenic mechanisms are the predominate drivers of long-lasting immune dysregulation and are thus important areas for ongoing research into interventional targets to improve the health of PLWH.